Skip to main content
. 2024 Mar 21;2024:7588928. doi: 10.1155/2024/7588928

Table 3.

Risk factors associated with cancer incidence and mortality among PLHIV.

Risks for cancer incidence (N = 15 studies) HIV infection/longer duration with HIV infection Opportunistic infections Increasing age/age > 45 years/age > 50 years Low CD4/CD4 < 50/CD4 < 200 Lack of viral load suppression Male gender Smoking/tobacco use Clinical AIDS comorbidity Cancer history Absence of ART
Any cancer 2 (13.3%) 3 (20%) 2 (13.3%) 1 (6.7%) 1 (6.7%) 1 (6.7%) 1 (6.7%)
ADCs 1 (6.7%) 3 (20.0%) 1 (6.7%) 1 (6.7%)
NADCs 2 (13.3%) 5 (33.3%) 3 (20.0%) 1 (6.7%) 1 (6.7%) 1 (6.7%)
Risks for cancer mortality (N = 7 studies) Poor immune status Lack of cancer treatment Cancer staging 3 or 4/cancer progression/relapse Increasing age/age > 45/>50/>55 years Nadir CD4 < 200/CD4 < 100 Failure to suppress HIV RNA/viral load > 400 Time since HIV infection (>5 years) Previous AIDS/AIDS comorbidity Not on ART Male gender
Any cancer 1 (14.2%) 1 (14.2%) 1 (14.2%) 2 (28.6%) 2 (28.6%) 1 (14.2%) 1 (14.2%)
ADCs 2 (28.6%) 1 (14.2%)
NADCs 1 (14.2%) 2 (28.6%) 2 (28.6%) 1 (14.2%) 2 (28.6%)

Same study. PLHIV: people living with HIV; HIV: human immunodeficiency virus; RNA: ribonucleic acid; ADCs: AIDS-defining cancers; NADCs: non-AIDS-defining cancers; ART: antiretroviral therapy.